1. EMA guideline on the investigation of bioequivalence. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 24 June 2022.
2. EMA: Questions and answers on bioequivalence studies. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers. Accessed 24 June 2022.
3. FDA guideline on bioequivalence. Guidance for industry bioavailability and bioequivalence studies submitted in NDAs or INDs—general considerations. https://www.fda.gov/files/drugs/published/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf. Accessed 24 June 2022.
4. Davit BM, Nwakama PE, Conner GP, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the united states food and drug administration. Ann Pharmacother. 2009;43:1583–97.
5. Approved products with therapeutic equivalence evaluation. 29th ed. Washington DC: US Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Office of pharmaceutical sciences, Office of generic drugs, 2009. https://www.fda.gov/media/71474/download. Accessed 24 June 2022.